Exclusive: Alzheimer’s jab halves rate of decline, study finds - The Telegraph

Direct Source Verification: This story is aggregated from The Telegraph (telegraph.co.uk). Full reporting rights and copyright belong to the primary publisher.
Laura Donnelly Health Editor, in Boston Show biography Laura has led award-winning coverage on the NHS, medical science breakthroughs, and public health policy across the UK for The Telegraph. Her reporting can be found on X: @lauradonnlee

Laura Donnelly Health Editor, in Boston Show biography Laura has led award-winning coverage on the NHS, medical science breakthroughs, and public health policy across the UK for The Telegraph. Her reporting can be found on X: @lauradonnlee

A jab given just twice a year has halved the rate of cognitive decline in Alzheimer’s patients, in results scientists described as “thrilling”.

In a major trial, patients given low-dose diranersen injections showed 54 per cent less decline on a test of memory and thinking over almost two years. The findings suggest that the treatment could prove the most powerful yet to slow Alzheimer’s.

It is also the first to show a reduction in tau, a protein that forms damaging tangles linked to brain cell death.

The treatment uses gene-silencing technology to tackle disease at its source, blocking the RNA messages that tell brain cells to produce tau.

Prof Jeffrey Cummings, a co-author of the study, told the Clinical Trials on Alzheimer’s Disease conference in Boston: “We reversed Alzheimer pathology. We removed tau tangles. That’s a remarkable statement.”

Prof Reisa Sperling, also a co-author of the study and professor of neurology at Harvard Medical School, who presented the brain scan findings, described them as “thrilling”.

“These data suggest that we’re not just slowing the accumulation of tau, but we are lowering aggregated tau from baseline,” she said.

British patients are already asking to join the next trial of the drug, with UK recruitment expected to start in spring.

Scientists believe that several processes work together to drive Alzheimer’s. Amyloid builds up in plaques between brain cells, while tau forms tangles inside them. The brain’s immune cells try to clear the debris, but persistent inflammation can cause further damage.

The trial, funded by Biogen, is the first to show that lowering tau can slow progression of Alzheimer’s.

The first drugs licensed in the UK to slow Alzheimer’s target amyloid.

With more than 160 drugs now in development, some experts believe that the best hope of halting the disease may lie in a cocktail of treatments that tackle several of these processes at once.

But there is concern that the UK is falling behind, with the first breakthrough drugs shown to slow progression of the disease blocked from NHS use. In The Telegraph last week, Lord Cameron urged Andy Burnham to make breakthrough treatments available for patients on the NHS.

Diranersen was discovered by Ionis Pharmaceuticals and is being developed by Biogen.

Dr Lawren VandeVrede, a trial investigator at the University of California, San Francisco, described the findings as “really exciting”, saying that they raised hopes that patients could remain in the early stages of Alzheimer’s for twice as long.

“That’s a doubling of the time in the early stages of disease,” he told delegates, although longer follow-up is needed to establish whether the benefits last.

The international phase two trial, called CELIA, enrolled 416 people with early Alzheimer’s, including mild cognitive impairment and mild dementia, to compare three dosing regimens with a placebo.

The strongest results came from the group of 60 patients given the lowest dose, 60mg every 24 weeks, through an injection into the spinal fluid in the lower back.

Highlighting that treatment was administered just “twice a year”, Prof Cummings said: “I don’t think we emphasise that enough.”

Of those who completed the initial 76-week study, nine in 10 chose to continue. At 96 weeks, those treated from the outset were compared with participants originally assigned a placebo, who had since received either no active treatment or just one dose.

On the test of memory and thinking, patients in the lowest-dose group showed 54 per cent less decline at 96 weeks. On a broader measure that also assessed how well patients managed everyday tasks, the difference was 38 per cent.

The findings suggest a potentially greater effect than existing Alzheimer’s drugs. Lecanemab, one of two recently licensed treatments, slowed clinical decline by 27 per cent in trials, while donanemab achieved 35 per cent on a different measure.

However, the results cannot be directly compared because the studies used different methods and patient groups.

Prof Sperling said reductions had been seen particularly in areas where substantial amounts of tau had accumulated, including regions important for memory. She described decreases in tau “that’s likely been there for many years”.

Prof Cath Mummery, of University College London, a co-author of the study, said of the planned next trial, which will recruit British participants: “There are already patients asking me to go into it.”

When findings were first presented earlier this summer, the study was found to have missed its original primary endpoint, which was to see whether increasing the dose produced greater benefit.

The best response came from the lowest dose, suggesting that researchers may have found a sweet spot where less treatment delivers greater benefits.

The experts stressed that the findings need confirmation in a larger phase three trial. Researchers said treatment was generally well tolerated. Side effects included pain associated with lumbar punctures, headaches and confusion, which was more common at higher doses.

Susan Kohlhaas, the executive director of research and partnerships at Alzheimer’s Research UK, said the breakthrough was part of “a new era” in Alzheimer’s treatment and warned that Britain risked being left behind.

“We’re now at a point in the field where we’re seeing a lot of exciting advances, and they’re coming thick and fast,” she said.

She urged the NHS to act, saying the first drugs shown to slow the disease were “still” unavailable “even to a small number of people on the NHS in the UK”.

Original Source
https://www.telegraph.co.uk/news/2026/11/18/alzheimers-jab-halves-rate-of-decline-study-finds/
Visit The Telegraph ↗
SHARE STORY:
𝕏 f in

Related Coverage in Health